These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 10087004)
41. Effects of niravoline (RU 51599), a selective kappa-opioid receptor agonist on intracranial pressure in gradually expanding extradural mass lesion. Bemana I; Nagao S J Neurotrauma; 1998 Feb; 15(2):117-24. PubMed ID: 9512087 [TBL] [Abstract][Full Text] [Related]
42. Mechanisms of the therapeutic effect of astragalus membranaceus on sodium and water retention in experimental heart failure. Ma J; Peng A; Lin S Chin Med J (Engl); 1998 Jan; 111(1):17-23. PubMed ID: 10322646 [TBL] [Abstract][Full Text] [Related]
43. Effects of receptor blockade on metabolism and renal actions of vasopressin in conscious dogs. Grove L; Christensen P; Bie P Acta Physiol Scand; 1998 May; 163(1):93-101. PubMed ID: 9648627 [TBL] [Abstract][Full Text] [Related]
44. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Wong F; Blei AT; Blendis LM; Thuluvath PJ Hepatology; 2003 Jan; 37(1):182-91. PubMed ID: 12500203 [TBL] [Abstract][Full Text] [Related]
45. Temporal relationship between the decrease in arterial pressure and sodium retention in conscious spontaneously hypertensive rats with carbon tetrachloride-induced cirrhosis. López C; Jiménez W; Arroyo V; Clària J; La Villa G; Asbert M; Gaya J; Rivera F; Rodés J Hepatology; 1991 Mar; 13(3):585-9. PubMed ID: 1999328 [TBL] [Abstract][Full Text] [Related]
46. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study. Thuluvath PJ; Maheshwari A; Wong F; Yoo HW; Schrier RW; Parikh C; Steare S; Korula J Aliment Pharmacol Ther; 2006 Sep; 24(6):973-82. PubMed ID: 16948809 [TBL] [Abstract][Full Text] [Related]
47. Lithium effectively complements vasopressin V2 receptor antagonist in the treatment of hyponatraemia of SIADH rats. Kazama I; Arata T; Michimata M; Hatano R; Suzuki M; Miyama N; Sanada S; Sato A; Satomi S; Ejima Y; Sasaki S; Matsubara M Nephrol Dial Transplant; 2007 Jan; 22(1):68-76. PubMed ID: 16702208 [TBL] [Abstract][Full Text] [Related]
48. Molecular analysis of impaired urinary diluting capacity in glucocorticoid deficiency. Wang W; Li C; Summer SN; Falk S; Cadnapaphornchai MA; Chen YC; Schrier RW Am J Physiol Renal Physiol; 2006 May; 290(5):F1135-42. PubMed ID: 16352742 [TBL] [Abstract][Full Text] [Related]
49. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Tsuboi Y; Ishikawa S; Fujisawa G; Okada K; Saito T Kidney Int; 1994 Jul; 46(1):237-44. PubMed ID: 7933842 [TBL] [Abstract][Full Text] [Related]
50. Aquaretic effects of the nonpeptide V2 antagonist OPC-31260 in hydropenic humans. Shimizu K Kidney Int; 1995 Jul; 48(1):220-6. PubMed ID: 7564082 [TBL] [Abstract][Full Text] [Related]
52. Renal responses to chronic cold exposure. Sun Z; Zhang Z; Cade R Can J Physiol Pharmacol; 2003 Jan; 81(1):22-7. PubMed ID: 12665254 [TBL] [Abstract][Full Text] [Related]
53. Usefulness of niravoline, an arginine vasopressin inhibitor, on tumour-origin brain oedema. Takahashi H; Hamada H; Teramoto A Acta Neurochir Suppl; 2000; 76():323-7. PubMed ID: 11450035 [TBL] [Abstract][Full Text] [Related]
54. Aquaretic effect of the stable dynorphin-A analog E2078 in the human. Ohnishi A; Mihara M; Yasuda S; Tomono Y; Hasegawa J; Tanaka T J Pharmacol Exp Ther; 1994 Jul; 270(1):342-7. PubMed ID: 7913498 [TBL] [Abstract][Full Text] [Related]
55. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites. Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Katsaraki A; Tsianos EV Nephrol Dial Transplant; 2005 Aug; 20(8):1623-9. PubMed ID: 15886218 [TBL] [Abstract][Full Text] [Related]
56. Prevention of hypoxic brain oedema by the administration of vasopressin receptor antagonist OPC-31260. Molnár AH; Varga C; Berkó A; Rojik I; Párducz A; László F; László FA Prog Brain Res; 2008; 170():519-25. PubMed ID: 18655905 [TBL] [Abstract][Full Text] [Related]
57. Effect of chronic administration of sildenafil on sodium retention and on the hemodynamic complications associated with liver cirrhosis in the rat. Ghali-Ghoul R; Tahseldar-Roumieh R; Sabra R Eur J Pharmacol; 2007 Oct; 572(1):49-56. PubMed ID: 17610866 [TBL] [Abstract][Full Text] [Related]